Identification of recombinant human EPO variants in greyhound plasma and urine by ELISA, LC‐MS/MS and western blotting: a comparative study. Issue 2 (19th August 2015)

• Record Type: Journal Article
• Authors: Timms, Mark; Steel, Rohan; Vine, John
• Is Part Of: Drug testing and analysis. Volume 8:Issue 2(2016:Feb.)
• Page Start: 164
• Page End: 176
• Publication Date: 2015-08-19
• Subjects: greyhounds -- erythropoietin -- western blotting -- ELISA -- Eprex® -- Aranesp® -- Mircera®; Drugs -- Analysis -- Periodicals; Drug testing -- Periodicals; Chemistry, Forensic -- Periodicals; 615.1901
• DOI: 10.1002/dta.1835
• Languages: English
• ISSNs: 1942-7603

Abstract

Abstract : The recombinant human erythropoietins epoetin alfa (Eprex®), darbepoetin (Aranesp®) and methoxy polyethylene glycol‐epoetin beta (Mircera®) were administered to greyhounds for 7, 10 and 14 days respectively. Blood and urine samples were collected and analysed for erythropoietin by ELISA, LC‐MS/MS and western blotting. Limits of confirmation in plasma for western blotting and LC‐MS/MS methods ranged from a low of 2.5mIU/mL, and closely matched the sensitivity of ELISA screening. Copyright © 2015 John Wiley & Sons, Ltd. Abstract : Epoetin alfa, darbopoietin and pegylated Epoetin beta were administered to greyhounds and recombinant human EPO detected in plasma and urine samples by ELISA, LC‐MS/MS and western blotting.